G A Hale

Summary

Affiliation: St. Jude Children's Research Hospital
Country: USA

Publications

  1. ncbi request reprint Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease
    G A Hale
    Division of Blood and Marrow Transplantation, Markey Cancer Center, University of Kentucky, 800 Rose Street, Lexington, Kentucky 40536, USA
    Cancer Treat Rev 26:411-27. 2000
  2. ncbi request reprint Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children
    Gregory A Hale
    Division of Stem Cell Transplantation, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Biol Blood Marrow Transplant 11:912-20. 2005
  3. ncbi request reprint Autologous hematopoietic stem cell transplantation for pediatric solid tumors
    Gregory A Hale
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Expert Rev Anticancer Ther 5:835-46. 2005
  4. doi request reprint Perspective on the role of haploidentical transplantation in the management of hematologic malignancies: why do it?
    Gregory A Hale
    Division of Bone Marrow Transplantation, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Curr Hematol Malig Rep 2:202-7. 2007
  5. ncbi request reprint Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome
    G A Hale
    Division of Stem Cell Transplantation, Department of Hematology Oncology, St Jude s Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Biol Blood Marrow Transplant 9:698-705. 2003
  6. ncbi request reprint Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation
    G A Hale
    Department of Hematology/Oncology, St Jude Children's Research Hospital, Memphis, TN 38105-2794, USA
    Bone Marrow Transplant 27:155-62. 2001
  7. ncbi request reprint Dental abnormalities in children preparing for pediatric bone marrow transplantation
    M D Vaughan
    Department of Pediatric Dentistry, University of Tennessee Health Science Center, Memphis, TN, USA
    Bone Marrow Transplant 36:863-6. 2005
  8. ncbi request reprint Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen
    G A Hale
    Department of Hematology Oncology, Memphis, TN 38105 2794, USA
    Bone Marrow Transplant 31:981-6. 2003
  9. ncbi request reprint Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study
    G L Phillips
    Blood and Marrow Transplant Program, University of Kentucky, Lexington, USA
    Biol Blood Marrow Transplant 10:473-83. 2004
  10. pmc Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma
    W Leung
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Br J Cancer 97:539-42. 2007

Detail Information

Publications45

  1. ncbi request reprint Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease
    G A Hale
    Division of Blood and Marrow Transplantation, Markey Cancer Center, University of Kentucky, 800 Rose Street, Lexington, Kentucky 40536, USA
    Cancer Treat Rev 26:411-27. 2000
    ..Also, when combined with lesser intensity conditioning, such may permit patients who otherwise would not be candidates for standard transplant regimens to be allografted...
  2. ncbi request reprint Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children
    Gregory A Hale
    Division of Stem Cell Transplantation, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Biol Blood Marrow Transplant 11:912-20. 2005
    ..With a multiple regression analysis, the use of antithymocyte globulin (beta = .86; P = .04) and recipient cytomegalovirus seronegativity (beta = .93; P = .035) remained significant risk factors for the development of HUS...
  3. ncbi request reprint Autologous hematopoietic stem cell transplantation for pediatric solid tumors
    Gregory A Hale
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Expert Rev Anticancer Ther 5:835-46. 2005
    ....
  4. doi request reprint Perspective on the role of haploidentical transplantation in the management of hematologic malignancies: why do it?
    Gregory A Hale
    Division of Bone Marrow Transplantation, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Curr Hematol Malig Rep 2:202-7. 2007
    ..Because most patients do not have a matched related donor available and time to identify an unrelated donor may be excessive, haploidentical HSCT is a potentially curative option for these patients...
  5. ncbi request reprint Hemorrhagic cystitis after allogeneic bone marrow transplantation in children: clinical characteristics and outcome
    G A Hale
    Division of Stem Cell Transplantation, Department of Hematology Oncology, St Jude s Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Biol Blood Marrow Transplant 9:698-705. 2003
    ..032), or antithymocyte globulin (P =.0446). Multiple regression analysis revealed male sex (beta =.97; P =.027) and unrelated donor graft recipients (beta =.83; P =.039) to be significant factors...
  6. ncbi request reprint Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation
    G A Hale
    Department of Hematology/Oncology, St Jude Children's Research Hospital, Memphis, TN 38105-2794, USA
    Bone Marrow Transplant 27:155-62. 2001
    ..Eight patients (two of whom also relapsed) died of RRT. Although RRT and relapse remain significant problems, a significant percentage of pediatric patients failing ABMT may be cured with alloBMT...
  7. ncbi request reprint Dental abnormalities in children preparing for pediatric bone marrow transplantation
    M D Vaughan
    Department of Pediatric Dentistry, University of Tennessee Health Science Center, Memphis, TN, USA
    Bone Marrow Transplant 36:863-6. 2005
    ..Dental abnormalities are prevalent in children undergoing BMT. Pre-transplant oral hygiene and dental examination should be standard care in order to minimize potential sites of infection...
  8. ncbi request reprint Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen
    G A Hale
    Department of Hematology Oncology, Memphis, TN 38105 2794, USA
    Bone Marrow Transplant 31:981-6. 2003
    ..We conclude that a conditioning regimen containing TBI but not etoposide is effective in allogeneic BMT for children with histiocytic diseases...
  9. ncbi request reprint Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study
    G L Phillips
    Blood and Marrow Transplant Program, University of Kentucky, Lexington, USA
    Biol Blood Marrow Transplant 10:473-83. 2004
    ..Further studies are needed not only to confirm these findings, but also to define the antitumor efficacy of this regimen. Finally, it may be possible to evaluate additional methods of further dose escalation of melphalan in this setting...
  10. pmc Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma
    W Leung
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Br J Cancer 97:539-42. 2007
    ..01). The potential applicability of the receptor-ligand mismatch model to autologous HCTs and to patients with lymphoma or solid tumour is clinically significant because of the prevalence of the HCT procedure...
  11. ncbi request reprint Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
    G L Phillips
    Blood and Marrow Transplant Program, University of Kentucky, Lexington, KY, USA
    Bone Marrow Transplant 33:781-7. 2004
    ..This experience may be used as a starting point for subsequent dose escalation of HDMEL (probably with AF) in established combination regimens...
  12. ncbi request reprint Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acute lymphoblastic leukemia
    R C Barfield
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 48:349-53. 2007
    ..Because his ALL blasts expressed CD34 but lacked CD133, he received a CD133 selected autologous graft following high-dose consolidation chemotherapy. The patient survives in remission 19 months after HSCT...
  13. ncbi request reprint Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer
    D E Reece
    University of Kentucky, Blood and Marrow Transplant Program, Lexington, KY, USA
    Clin Breast Cancer 2:52-8. 2001
    ..Moreover, in this interim analysis, patients with the most vigorous humoral and cellular immune responses had a significant improvement in progression-free survival. Further follow-up and evaluation of this approach is warranted...
  14. pmc A novel approach for quantification of KIR expression in healthy donors and pediatric recipients of hematopoietic SCTs
    X Chen
    Department of Oncology, Division of Bone Marrow Transplantation and Cellular Therapy, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Bone Marrow Transplant 43:525-32. 2009
    ..Stem cell mobilization caused a transient increase of KIR expression. We conclude that KIR expression differs quantitatively with age and primary disease and is transiently altered by stem cell recruitment and selection...
  15. pmc Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma
    J T Sandlund
    Department of Oncology, St Jude Children s Research Hospital, University of Tennessee, Memphis, TN, USA
    Ann Oncol 22:468-71. 2011
    ..Children with recurrent or refractory malignant lymphoma generally have a poor prognosis. There is a need for new active drug combinations for this high-risk group of patients...
  16. ncbi request reprint Bone mineral density and osteonecrosis in survivors of childhood allogeneic bone marrow transplantation
    S C Kaste
    Department of Diagnostic Imaging, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Bone Marrow Transplant 33:435-41. 2004
    ..d. We conclude that pediatric alloBMT survivors have decreased BMD and are at risk of osteonecrosis. They should be monitored to assure early intervention that may ameliorate adverse outcomes...
  17. ncbi request reprint Dental abnormalities after pediatric bone marrow transplantation
    M D Vaughan
    Department of Pediatric Dentistry, University of Tennessee Health Science Center, Memphis, TN 38105 2794, USA
    Bone Marrow Transplant 36:725-9. 2005
    ..001), but there was no significant change in the frequency of other dental abnormalities after BMT. Dental abnormalities are prevalent in survivors of childhood BMT, but only root stunting appeared to progress with BMT...
  18. ncbi request reprint Energy expenditure in children undergoing hematopoietic stem cell transplantation
    K A Ringwald-Smith
    Clinical Nutrition Services, Department of Hematology Oncology, University of Tennessee, College of Medicine, Memphis, TN, USA
    Bone Marrow Transplant 30:125-30. 2002
    ..Until accurate equations have been identified for estimating these patients' needs, the use of indirect calorimetry may be medically warranted...
  19. ncbi request reprint A novel approach for the analysis of T-cell reconstitution by using a T-cell receptor beta-based oligonucleotide microarray in hematopoietic stem cell transplantation
    Xiaohua Chen
    Division of Bone Marrow Transplantation, St Jude Children s Research Hospital, MaiJ Stop 321, 332 N Lauderdale Street, Memphis, TN 38105 2794, USA
    Exp Hematol 35:831-41. 2007
    ..In this study, we designed the first TCRbeeta-based oligonucleotide microarray and investigated its specificity, clonality discrimination, sensitivity of detection, and feasibility for monitoring T-cell population diversity in HSCT...
  20. ncbi request reprint A prospective cohort study of late sequelae of pediatric allogeneic hematopoietic stem cell transplantation
    Wing Leung
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Medicine (Baltimore) 86:215-24. 2007
    ..2%, and male hypogonadism 20.3%. Coexistence of multiple late sequelae was common in HSCT survivors. Our findings provide a basis for more effective patient counseling, optimal surveillance, and early intervention...
  21. ncbi request reprint Diagnostic yield of bronchoalveolar lavage is low in allogeneic hematopoietic stem cell recipients receiving immunosuppressive therapy or with acute graft-versus-host disease: the St. Jude experience, 1990-2002
    Kimberly A Kasow
    Division of Bone Marrow Transplantation, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Biol Blood Marrow Transplant 13:831-7. 2007
    ....
  22. doi request reprint High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors
    Chie Schin Shih
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer 112:1345-53. 2008
    ..High-dose chemotherapy (HDCT) with autologous stem cell rescue (ASCR) has been reported to be effective in treating children with recurrent central nervous system (CNS) malignancies...
  23. pmc Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission
    David I Marks
    Adult Blood and Marrow Transplantation BMT Unit, United Bristol Healthcare Trust, Bristol, United Kingdom
    Blood 112:426-34. 2008
    ..Nearly 40% of adults with ALL in CR1 survive 5 years after URD transplantation. Relapse risks were modest; TRM is the major cause of treatment failure. Selecting closely HLA-matched URD and reducing TRM should improve results...
  24. pmc Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant
    Sonali M Smith
    Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA
    Biol Blood Marrow Transplant 14:904-12. 2008
    ..HCT2 should be considered for patients with relapsed HL or NHL after HCT1 without alternative allogeneic stem cell transplant options...
  25. pmc Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
    Stephanie J Lee
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 112:3500-7. 2008
    ..Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT...
  26. pmc Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma
    Maryam Fouladi
    Department of Oncology, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105 2794, USA
    J Clin Oncol 26:3749-55. 2008
    ....
  27. pmc HLA-matched sibling hematopoietic stem cell transplantation for fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens
    Ricardo Pasquini
    Federal University of Parana, Curitiba, Brazil
    Biol Blood Marrow Transplant 14:1141-7. 2008
    ..As the peak time for developing solid tumors after HCT is 8 to 9 years, longer follow-up is required before definitive statements can be made regarding the impact of nonirradiation regimens on cancer risk...
  28. pmc Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning
    Parameswaran Hari
    Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    Biol Blood Marrow Transplant 14:236-45. 2008
    ..Although disease-free survival (DPS) is similar compared to myeloablative conditioning, an increased risk of late disease progression after RIC is concerning...
  29. ncbi request reprint Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research
    Julie A Panepinto
    Department of Hematology Oncology Bone Marrow Transplant, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
    Br J Haematol 137:479-85. 2007
    ....
  30. ncbi request reprint CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients
    Kimberly A Kasow
    Division of Bone Marrow Transplantation, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Biol Blood Marrow Transplant 13:608-14. 2007
    ..Our study demonstrates that CD34(+)-selection of marrow grafts is feasible, and these grafts are able to successfully reconstitute hematopoiesis in patients undergoing autologous BMT...
  31. ncbi request reprint Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse
    Stephanie J Lee
    Graft vs Host Disease Working Committee of the International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, WI, USA
    Blood 100:406-14. 2002
    ..Survival and disease-free survival of the most favorable cGVHD group in each scheme were similar, or better, than those of patients without cGVHD; these patients may not need aggressive or extended immune suppression...
  32. ncbi request reprint Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses
    Olle Ringden
    Division of Clinical Immunology F79, Huddinge University Hospital, S 141 86 Huddinge, Sweden
    Br J Haematol 121:874-85. 2003
    ..34, P = 0.003), lower risk of relapse (RR = 0.62, P = 0.029) and treatment failure (RR = 0.74, P = 0.03). We conclude that higher CD34 cell doses decrease treatment failure in recipients of HLA-identical sibling BM and PBSC transplants...
  33. ncbi request reprint T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation
    Eric J Lowe
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Br J Haematol 123:323-6. 2003
    ..In contrast, donor T-cell incompatibility was a risk factor for acute GVHD, chronic GVHD and death. Thus, T-cell alloreactivity dominated that of NK cells in minimally T-cell-depleted grafts...
  34. ncbi request reprint Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations
    Hakumei Oh
    GVHD Immune Reconstitution Wroking Committee of the International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milaukee, WI, USA
    Blood 105:1408-16. 2005
    ..04) and chronic (RR = 3.16; P = .002) GVHD. No differences in other clinical outcomes were noted. Our findings suggest that ethnicity may influence the risk for GVHD, though overall survival rates after transplantation remain similar...
  35. ncbi request reprint Brain parenchymal damage after haematopoietic stem cell transplantation for severe sickle cell disease
    Paul Woodard
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 N Lauderdale Street, Lauderdale, Memphis, TN 38105, USA
    Br J Haematol 129:550-2. 2005
    ..Transient changes occurred early in two patients. Persistent changes occurred in five. Parenchymal lesions occurred in zero of two patients without prior lacunae or infarcts and in all seven with prior lacunae or infarcts (P = 0.0278)...
  36. pmc Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation
    Hanna J Khoury
    Center for International Blood and Marrow Transplant Research CIBMTR, Health Policy Institute, Medical College of Wisconsin, Milwaukee, USA
    Blood 107:1712-6. 2006
    ..In conclusion, results of this study found no long-term benefit or disadvantage of giving G-CSF after transplantation to promote hematopoietic recovery...
  37. ncbi request reprint Autologous stem cell transplantation for small cell lung cancer
    J Douglas Rizzo
    Statistical Center, Health Policy Institute, Medical College of Wisconsin, Milwaukee 53226, USA
    Biol Blood Marrow Transplant 8:273-80. 2002
    ..Transplantation for patients with extensive disease does not appear to produce substantial benefit...
  38. ncbi request reprint EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation
    Kimberly A Kasow
    Department of Hematology Oncology, Division of Stem Cell Transplantation, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Pediatr Blood Cancer 49:869-72. 2007
    ..She subsequently developed disseminated PTLPD involving multiple organ and nodal sites. Her neoplastic lymphoblasts were host-derived and refractory to rituximab treatment due to lack of CD20 expression...
  39. ncbi request reprint Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience
    Fariba Navid
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 106:1846-56. 2006
    ..Vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide are highly effective against pediatric sarcomas. The authors investigated the feasibility of administering these agents concomitantly within a defined period...
  40. ncbi request reprint Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients
    Usman Yusuf
    Division of Stem Cell Transplantation, Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Transplantation 81:1398-404. 2006
    ..We report our experience with cidofovir (CDV) for treatment of ADV infection in 57 HSCT patients, median age 8 years (range 0.5-26)...
  41. ncbi request reprint Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies
    Xiaohua Chen
    Division of Bone Marrow Transplantation, St Jude Children s Research Hospital, Memphis, TN, USA
    Br J Haematol 135:524-32. 2006
    ..Rapid T-cell reconstitution, retention of NK-cells in the graft and induction of low grade GvHD may also enhance the potential anti-cancer immune effect...
  42. ncbi request reprint Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial
    Amar Gajjar
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Lancet Oncol 7:813-20. 2006
    ..We aimed to investigate the effectiveness of risk-adapted radiotherapy followed by a shortened period of dose-intense chemotherapy in children with medulloblastoma...
  43. ncbi request reprint Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation
    Rupert Handgretinger
    Children s University Hospital, University of Tuebingen, Hoppe Seyler Strasse 1, 72076 Tuebingen, Germany
    Ann N Y Acad Sci 1106:279-89. 2007
    ..For chemorefractory patients, additional posttransplant cellular and humoral immunotherapeutic strategies are needed for prevention of relapse after transplantation...
  44. ncbi request reprint Establishing the use of body mass index as an indicator of nutrition risk in children with cancer
    Joshua Nething
    St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    JPEN J Parenter Enteral Nutr 31:53-7. 2007
    ....
  45. ncbi request reprint Molecular monitoring of immune reconstitution after haploidentical stem cell transplantation
    Xiaohua Chen
    Division of Bone Marrow Transplantation and Cellular Therapy, Department of Oncology, St Jude Children s Research Hospital, Mail Stop 260, 332N Lauderdale St, Memphis TN 38105 2794, USA
    Curr Stem Cell Res Ther 3:75-8. 2008
    ..We also propose future directions for clinical research incorporating these novel concepts...